Insider holders · CIK 0000109657
GT Biopharma, Inc. · GTBP
Every insider with a reported Table I holding at this company, ranked by their last-reported share count. A balance is only as fresh as its filing — the report date sits next to every row on purpose. ← Back to activity
| Insider | Direct shares | Indirect shares | Total reported | Last report (ET) | From |
|---|---|---|---|---|---|
| Kathleen Clarence-SmithCEO | 8,505,633 | — | 8,505,633 | Dec 1, 2017 · 5:25 pm EST | Form 3 |
| Mark J Silverman10% Owner | 8,172,079 | — | 8,172,079 | Dec 1, 2017 · 5:06 pm EST | Form 3 |
| Tony CataldoDirector | 4,029,600 | — | 4,029,600 | Feb 13, 2019 · 11:22 am EST | Form 4 |
| Steven W WeldonCFO | 2,568,840 | — | 2,568,840 | Dec 1, 2017 · 5:17 pm EST | Form 4 |
| BRISTOL CAPITAL LLC10% Owner | 2,441,148 | — | 2,441,148 | Jan 25, 2016 · 4:37 pm EST | Form 3 |
| Raymond W. UrbanskiChief Medical Officer | 1,528,989 | — | 1,528,989 | Dec 1, 2017 · 5:35 pm EST | Form 3 |
| BRISTOL INVESTMENT FUND LTD10% Owner | 463,806 | — | 463,806 | Apr 5, 2016 · 6:05 pm EDT | Form 4 |
Balances come from each insider’s most recent filing that reports a Table I holding; an insider who left the company years ago still appears with their last-known figure and its date. Indirect totals collapse multiple vehicles (trusts, LLCs) into one number — open the filing for the breakdown. Shares as filed, not split-adjusted.